Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
53.69%
Operating Margin
50.65%
Net Margin
41.65%
Efficiency Metrics
Revenue per Expense Ratio
2.03
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
92.19%
Income Tax Rate
20.80%
EPS
3.9600000000
Balance Sheet Analysis
Current Ratio
0.63
Cash Ratio
0.13
Working Capital
$-162.00M
Debt to Equity
0.79
Debt to Assets
36.41%
Equity Ratio
46.08%
Cash Flow Analysis
Operating Cash Flow Ratio
132.86%
Free Cash Flow Ratio
49.13%
CapEx to Revenue
83.73%
Dividends Paid
$263.00M
Stock Buybacks
No buybacks
Total Shareholder Returns
$263.00M
Cash Position Change
-8.20%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 7.56%
Detailed Growth Metrics
Core Performance
Revenue
0.22%
Net Income
3.78%
EPS
3.39%
Operating Income
-2.30%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
15.00%
Operating Cash Flow
10.07%
Free Cash Flow
-93.28%
Balance Sheet Health
Assets
1.69%
Debt
-4.50%
Book Value per Share
2.82%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
7.56%
Shares Outstanding
0.21%
Long Term Trends
3Y Revenue/Share
22.24%
5Y Revenue/Share
90.03%
3Y Dividend/Share
0.00%
5Y Dividend/Share
0.00%